Lion Bioscience this week posted the second consecutive profitable quarter for its bioinformatics business, which is still up for sale, and said that it is considering a change to the business model for its non-bioinformatics operations, which is currently structured as a holding company.

While the firm did not provide an updated timeline for the sale of its bioinformatics group, which has been on the block since last May, CFO Peter Willinger told BioInform that although the sales process has taken longer than initially expected, it "hasn't stopped."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.